Fjarde AP Fonden Fourth Swedish National Pension Fund Buys 176,800 Shares of Boston Scientific Corporation $BSX

Posted by Stanley Muller on Jul 4th, 2026

Boston Scientific logo Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 62.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 461,370 shares of the medical equipment provider’s stock after acquiring an additional 176,800 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Boston Scientific were worth $28,951,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of BSX. Norges Bank purchased a new position in shares of Boston Scientific during the fourth quarter valued at about $2,199,395,000. Assenagon Asset Management S.A. lifted its position in shares of Boston Scientific by 133.6% in the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock worth $631,135,000 after buying an additional 5,751,760 shares in the last quarter. Maverick Capital Ltd. purchased a new stake in shares of Boston Scientific in the fourth quarter worth about $280,735,000. Farallon Capital Management LLC boosted its stake in Boston Scientific by 56.7% during the fourth quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider’s stock valued at $709,362,000 after buying an additional 2,693,007 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Boston Scientific by 31.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 11,035,628 shares of the medical equipment provider’s stock valued at $1,052,247,000 after buying an additional 2,668,230 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director David C. Habiger acquired 2,250 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the transaction, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 9,800 shares of company stock valued at $554,012 over the last three months. 0.34% of the stock is owned by company insiders.

Analysts Set New Price Targets

BSX has been the topic of a number of research reports. Truist Financial reduced their price objective on Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a research note on Thursday, June 4th. Stifel Nicolaus cut their target price on shares of Boston Scientific from $75.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, June 25th. The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a research report on Thursday, May 28th. Robert W. Baird set a $70.00 price target on shares of Boston Scientific in a research note on Thursday, May 28th. Finally, Barclays lowered their price objective on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.36.

View Our Latest Stock Report on BSX

Boston Scientific Price Performance

NYSE:BSX opened at $45.09 on Friday. The firm has a market capitalization of $67.01 billion, a price-to-earnings ratio of 18.86, a PEG ratio of 0.86 and a beta of 0.58. Boston Scientific Corporation has a 1 year low of $42.25 and a 1 year high of $109.50. The business has a 50 day simple moving average of $50.99 and a 200-day simple moving average of $69.43. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

About Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.